New agents for cancer chemoprevention

Journal of Cellular Biochemistry

Volumn 63, Issue SUPPL. 26, 1996, Pages 1-28

  Kelloff, Gary J ^a   Boone, Charles W ^a   Crowell, James A ^a   Steele, Vernon E ^a   Lubet, Ronald A ^a   Doody, Linda A ^b   Malone, Winfred F ^a   Hawk, Ernest T ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

cancer chemopreventive agents; DFMO; drug development; NSAIDs; oltipraz; Phase I clinical trials; Phase II clinical trials; retinoids

Indexed keywords

3 INDOLEMETHANOL; ALPHA TOCOPHEROL; ANASTROZOLE; AROMATASE INHIBITOR; BETA CAROTENE; COLECALCIFEROL; CURCUMIN; EFLORNITHINE; FINASTERIDE; GENISTEIN; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PHENETHYL ISOTHIOCYANATE; PRASTERONE; RETINOID; SELENOMETHIONINE; SULINDAC; TAMOXIFEN; URSODEOXYCHOLIC ACID; VOROZOLE; ANTINEOPLASTIC AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CONTENT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; ISOPRENYLATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; EXPERIMENTAL NEOPLASM; NEOPLASM; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030322859     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.240630703     Document Type: Article

References (413)

1. Boone, C.W., Kelloff, G.J. and Malone, W.E. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res. 50: 2-9, 1990.
2. Kelloff, G.J., Malone, W.F., Boone, C.W., Sigman, C.C. and Fay, J.R. Progress in applied chemoprevention research. Semin. Oncol. 17: 438-455, 1990.
3. Kelloff, G.J., Boone, C.W., Malone, W.F. and Steele, V. Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention. Boca Raton: CRC Press, 1992, pp. 41-56.
4. Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R. and Sigman, C.C. Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol. Biomarkers Prev. 3: 85-98, 1994.
5. Kelloff, G.J., Boone, C.W., Steeie, V.E., Crowell, J.A., Lubet, R. and Sigman, C.C. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res. 54: 2015S-1024S, 1994.
6. Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R. and Doody, L.A. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J. Cell. Biochem. 19: 1-9, 1994.
7. Kelloff, G.J., Johnson, J.R., Crowell, J.A., Boone, C.W., DeGeorge, J.J., Steele, V.E., Mehta, M.U., Temeck, J.W., Schmidt, W.J., Burke, G., Greenwald, P. and Temple, R.J. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomarkers Prev. 4: 1-10, 1995.
8. Boone, C.W., Kelloff, G.J. and Steele, V.E. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res. 52: 1651-1659, 1992.
9. Boone, C.W., Kelloff, G.J. and Freedman, L.S. Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action. J. Cell. Biochem. 17G: 14-25, 1993.
10. Fabian, C.J., Zalles, C., Kamel, S., McKittrick, R., Moore, W.P., Zeiger, S., Simon, C., Kimler, B., Cramer, A., Garcia, F. and Jewell, W. Biomarkers and cytologic abnormalities in women at high and low risk for breast cancer. J. Cell. Biochem. 17G: 153-160, 1993.
11. Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E. and Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 50: 2562-2568, 1990.
12. Rao, C.V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G. and Reddy, B.S. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51: 4528-4534, 1991.
13. Ratko, T.A., Detrisac, C.J., Dinger, N.M., Thomas, C.F., Kelloff, G.J. and Moon, R.C. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 49: 4472-4476, 1989.
14. Moon, R.C., Kelloff, G.J., Detrisac, C.J., Steele, V.E., Thomas, C.F. and Sigman, C.C. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 12: 1147-1154, 1992.
15. Moon, R.C., Rao, K.V.N., Detrisac, C.J., Kelloff, G.J., Steele, V.E. and Doody, L.A. Chemoprevention of respiratory tract neoplasia in the hamster by oltipraz, alone and in combination. Int. J. Oncol. 4: 661-667, 1994.
16. Moon, R.C., Kelloff, G.J., Detrisac, C.J., Steele, V.E., Thomas, C.F. and Sigman, C.C. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res. 14: 5-11, 1994.
17. Moldeus, P., Cotgreave, I.A. and Berggren, M. Lung protection by a thiol-containing antioxidant: N-Acetylcysteine. Respiration 50: 31-42, 1986.
18. Kensler, T.W. and Helzlsouer, K.J. Oltipraz: Clinical opportunities for cancer chemoprevention. J. Cell. Biochem. 22: 101-107, 1995.
19. Hong, W.K., Lippman, S.M., Itri, L.M., Karp, D.D., Lee, J.S., Byers, R.M., Schantz, S.P., Kramer, A.M., Lotan, R., Peters, L.J., Dimery, I.W., Brown, B.W. and Goepfert, H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323: 795-801, 1990.
20. Garewal, H.S. and Meyskens, F., Jr. Retinoids and carotenoids in the prevention of oral cancer: A critical appraisal. Cancer Epidemiol. Biomarkers Prev. 1: 155- 159, 1992.
21. Hong, W.K., Endicott, J., Itri, L.M., Doos, W., Batsakis, J.G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E.N., Vaughan, C., Toth, B.B., Kramer, A., Dimery, I.W., Skipper, P. and Strong, S. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 315: 1501-1505, 1986.
22. Lippman, S.M. and Hong, W.K. Chemoprevention of aerodigestive epithelial cancers. Adv. Exp. Med. Biol. 320: 151-161, 1992.
23. Meyskens, F.L., Jr., Surwit, E., Moon, T.E., Childers, J.M., Davis, J.R., Dorr, R.T., Johnson, C.S. and Alberts, D.S. Enhancement of regression of cervical intraepithelial neoplasia II (moderated dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J. Natl. Cancer Inst. 86: 539-543, 1994.
24. Hill, D.L. and Grubbs, C.J. Retinoids and cancer prevention. Annu. Rev. Nutr. 12: 161-181, 1992.
25. Torrisi, R., Pensa, F., Orengo, M.A., Catsafados, E., Ponzani, P., Boccardo, F., Costa, A. and Decensi, A. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res. 53: 4769-4771, 1993.
26. Sporn, M.B., Roberts, A.B., Glick, A.B., Luckert, P.H. and Pollard, M. Interactions of retinoids and transforming growth factor-beta in the chemoprevention of cancer. In: Sporn, M.B. (ed.) Control of Growth Factors and Prevention of Cancer. New York, NY: Springer-Verlag, 1992, pp. 37-46.
27. Sporn, M.B. and Roberts, A.B. Interactions of retinoids and transforming growth factor-β in regulation of cell differentiation and proliferation. Mol. Endocrinol. 5: 3-8, 1991.
28. Delia, D., Aiello, A., Lombardi, L., Pelicci, P.G., Grignani, F., Grignani, F., Formelli, F., Menard, S., Costa, A., Veronesi, U. and Pierotti, M.A. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. 53: 6036-6041, 1993.
29. Kelloff, G.J., Boone, C.W., Steele, V.E., Fay, J.R., Lubet, R.A., Crowell, J.A. and Sigman, C.C. Mechanistic considerations in chemopreventive drug development. J. Cell. Biochem. 20: 1-24, 1994.
30. De Palo, G., Veronesi, U., Camerini, T., Formelli, F., Mascotti, G., Boni, C., Fosser, V., Del Vecchio, M., Campa, T., Costa, A. and Marubini, E. Can fenretinide protect women against ovarian cancer? J. Natl. Cancer Inst. 87: 146-147, 1995.
31. Gould, M.N., Haag, J.D., Ariazi, E.A., Ren, Z., Shi, W., Elegbede, J.A., Clark, S.S. and Bailey, H.H. Anticancer activities of monoterpenes: A continuum between chemoprevention and chemotherapy. Proc. Annu. Meet. Am. Assoc. Cancer Res. 37: 655, 1996.
32. Pegg, A.E. and McCann, P.P. Polyamine metabolism and function. Am. J. Physiol. 243: C212-C221, 1982.
33. McCann, P.P., Pegg, A.E., Sjoerdsma, A. Inhibition of polyamine metabolism: Biological Significance and basis for new therapies. New York: Academic Press, 1987.
34. Luk, G.D. and Casero, R.A., Jr. Polyamines in normal and cancer cells. Adv. Enzyme Regul. 26: 91-105, 1987.
35. Weeks, C.E., Herrmann, A.L., Nelson, F.R. and Slaga, T.J. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc. Natl. Acad. Sci. USA 79: 6028- 6032, 1982.
36. Rozhin, J., Wilson, P.S., Bull, A.W. and Nigro, N.D. Ornithine decarboxylase activity in the rat and human colon. Cancer Res. 44: 3226-3230, 1984.
37. Kelloff, G.J., Croweil, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: 2-Difluromethylornithine (DFMO). J. Cell. Biochem. 20: 147-165, 1994.
38. Haegele, K.D., Alken, R.G., Grove, J., Schechter, P.J. and Koch-Weser, J. Kinetics of α-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase. Clin. Pharmacol. Ther. 30: 210-217, 1981.
39. Love, R.R, Carbone, P.P., Verma, A.K., Gilmore, D., Carey, P., Tutsch, K.D., Pomplun, M. and Wilding, G. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J. Natl. Cancer Inst. 85: 732-737, 1993.
40. Jaffa, B.M. Prostaglandins and cancer: An update. Prostaglandins 6: 453-467, 1974.
41. Karmali, R.A. Review: Prostaglandins and cancer. Prostaglandins Med. 5: 11-28, 1980.
42. Lombardino, J.G. and Wiseman, E.H. Piroxicam and other anti-inflammatory oxicams. Med. Res. Rev. 2: 127-152, 1982.
43. Zenser, T.V. and Davis, B.B. Arachidonic acid metabolism. In: Steele, V.R. Stoner, G.D., Boone, C.W. and Kelloff, G.J. (eds.) Cellular and Molecular Targets for Chemoprevention. Boca Raton, FL: CRC Press, 1992, 225-243.
44. Plescia, O.J., Smith, A.H. and Grinwich, K. Subversion of immune system by tumor cells and role of prostaglandins. Proc. Natl. Acad. Sci. USA 72: 1848-1851, 1975.
45. Goodwin, J.S. Immunologic effects of nonsteroidal anti-inflammatory drugs. Am. J. Med. 77: 7-15, 1984.
46. Singh, J., Kulkarni, N., Kelloff, G. and Reddy, B.S. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 15: 1317-1323, 1994.
47. Cohen, S.M., Zenser, T.V., Murasaki, G., Fukushima, S., Mattammal, M.B., Rapp, N.S. and Davis, B.B. Aspirin inhibition of AT-[4-(5-nitro-2-furyl)-2-thiazolyl]for mamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. Cancer Res. 41: 3355-3359, 1981.
48. Wild, D. and Degen, G.H. Prostaglandin H synthase- dependent mutagenic activation of heterocyclic aromatic amines of the IQ-type. Carcinogenesis 8: 541-545, 1987.
49. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: Aspirin. J. Cell. Biochem. 20: 74-85, 1994.
50. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: Ibuprofen. J. Cell. Biochem. 20: 197-204, 1994.
51. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: Piroxicam. J. Cell. Biochem. 20: 219-230, 1994.
52. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: Sulindac. J. Cell. Biochem. 20: 240-251, 1994.
53. Steele, V.E., Moon, R.C., Lubet, R.A., Grubbs, C.J., Reddy, B.S., Wargovich, M., McCormick, D.L, Pereira, M.A., Crowell, J.A., Bagheri, D., Sigman, C.C., Boone, C.W. and Kelloff, G.J. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI Chemoprevention Drug Development Program. J. Cell. Biochem. 20: 32-54, 1994.
54. Waddell, W.R., Ganser, G.F., Cerise, E.J. and Loughry, R.W. Sulindac for polyposis of the colon. Am. J. Surg. 157: 175-179, 1989.
55. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M. and Attali, P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639, 1991.
56. Thun, M.J., Namboodiri, M.M. and Heath, C.W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325: 1593-1596, 1991.
57. Giovannucci, E., Egan, K.M., Hunter, D.J., Stampfer, M.J., Colditz, G. A., Willett, W.C. and Speizer, F.E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333: 609-614, 1995.
58. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Strategy and planning for chemopreventive drug development: Clinical Development Plans. J. Cell. Biochem. 20: 55-62, 1994.
59. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: Oltipraz. J. Cell. Biochem. 20: 205-218, 1994.
60. Rao, C.V., Tokomo, K., Kelloff, G. and Reddy, B.S. Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis 12: 1051-1055, 1991.
61. Rao, C.V., Rivenson, A., Katiwalla, M., Kelloff, G.J. and Reddy, B.S. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res. 53: 2502-2506, 1993.
62. Rao, C.V., Rivenson, A., Zang, E., Steele, V., Kelloff, G. and Reddy, B.S. Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by oltipraz. Cancer Res. 56: 3395-3398, 1996.
63. Ansher, S.S., Dolan, P. and Bueding, E. Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity. Hepatology 3: 932-935, 1983.
64. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 6: 759- 763, 1985.
65. Kensler, T.W., Egner, P.A., Dolan, P.M., Groopman, J.D. and Roebuck, B.D. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 47: 4271-4277, 1987.
66. 1- induced hepatocarcinogenesis in F344 rats by5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res. 51: 5501-5506, 1991.
67. 1 in the rat. Toxicol. Appl. Pharmacol. 93: 442-451, 1988.
68. Gupta, E., Olopade, O.I., Ratain, M.J., Mick, R., Baker, T.M., Berezin, F.K., Benson, A.B., III and Dolan, M.E. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin. Cancer Res. 1: 1133-1138, 1995.
69. Primiano, T., Egner, P.A., Sutter, T.R., Kelloff, G.J., Roebuck, B.D. and Kensler, T.W. Intermittent dosing with oltipraz: Relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res. 55: 4319-4324, 1995.
70. Kensler, T.W. and Helzlsouer, K.J. Oltipraz: Clinical opportunities for cancer chemoprevention. J. Cell. Biochem. 22: 101-107, 1995.
71. Prochaska, H.J., Chavan, S.J., Baron, P. and Polsky, B. Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. J. Cell. Biochem. 22: 117-125, 1995.
72. Schwartz, A.G. and Pashko, L.L. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J. Cell. Biochem. 22: 210-217, 1995.
73. Lubet, R. A., McCormick, D.M., Gordon, G.M., Grubbs, C., Lei, X.-D., Prough, R.A., Steele, V.E., Kelloff, G.J., Thomas, C.F. and Moon, R.D. Effects of dehydroepiandrosterone on MNU-induced breast cancer in Sprague-Dawley rats. Ann. N.Y. Acad. Sci. 774: 340-341, 1995.
74. McCormick, D.L., Rao, K.V.N., Johnson, W.D., Bowman-Gram, T.A., Steele, V.E., Lubet, R.A. and Kelloff, G.J. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. Cancer. Res. 56: 1724-1726, 1996.
75. Schwartz, A.G., Lewbart, M.L. and Pashko, L.L. Inhibition of tumorigenesis by dehydroepiandrosterone and structural analogs. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992, pp. 443-455.
76. 1- and 7,12-dimethylbenz(a)anthracene-induced cytotoxicity and transformation in cultured cells. Cancer Res. 35: 2482-2487, 1975.
77. Feo, F., Pirisi, L., Pascale, R., Daino, L., Frassetto, S., Garcea, R. and Gaspa, L. Modulatory effect of glucose-6-phosphate dehydrogenase deficiency on benzo(a) pyrene toxicity and transforming activity for in vitro- cultured human skin fibroblasts. Cancer Res. 44: 3419-3425, 1984.
78. Feo, F., Ruggiu, M.E., Lenzerini, L., Garcea, R., Daino, L., Frassetto, S., Addis, V., Gaspa, L. and Pascale, R. Benzo(a)pyrene metabolism by lymphocytes from normal individuals and individuals carrying the Mediterranean variant of glucose-6-phosphate dehydrogenase. Int. J. Cancer 39: 560-564, 1987.
79. Pashko, L.L., Rovito, R.J., Williams, J.R., Sobel, E.L. and Schwarte, A.G. Dehydroepiandrosterone (DHEA) and 3β-methylandrost-5-en-17-one: Inhibitors of 7,12-dimethyl-benz[a] anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13- acetate (TPA)-promoted skin papilloma formation in mice. Carcinogenesis 5: 463-466, 1984.
80. Schwartz, A.G., Fairman, D.K., Polansky, M., Lewbart, M.L. and Pashko, L.L. Inhibition of 7,12-dimethyl-benz[a]anthracene-initiated and 12-O-tetradecanoyl phorbol-13-acetate-promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs. Carcinogenesis 10: 1809-1813, 1989.
81. Pashko, L.L., Schwartz, A.G., Abou-Gharbia, M. and Swern, D. Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids. Carcinogenesis 2: 717-721, 1981.
82. Schulz, S., Klann, R.C., Schonfeld, S. and Nyce, J.W. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: Role of isoprenoid biosynthesis. Cancer Res. 52: 1372-1376, 1992.
83. Schulz, S. and Nyce, J.W. Inhibition of protein isoprenylation and p21ras membrane association by dehydroepiandrosterone in human colonic adenocarcinoma cells in vitro. Cancer Res. 51: 6563-6567, 1991.
84. Knudsen, J.F. and Mahesh, V.B. Initiation of precocious sexual maturation in the immature rat treated with dehydroepiandrosterone. Endocrinology 97: 458-468, 1975.
85. Schwartz, A.G., Lewbart, M.L. and Pashko, L.L. Novel dehydroepiandrosterone analogues with enhanced biological activity and reduced side effects in mice and rats. Cancer Res. 48: 4817-4822, 1988.
86. Yamada, J., Sakurna, M., Ikeda, T., Fukuda, K. and Suga, T. Characteristics of dehydroepiandrosterone as a peroxisome proliferator. Biochim. Biophys. Acta 1092: 233-243, 1991.
87. Buster, I.E., Casson, P.R., Straughn, A.B., Dale, D., Umstot, E.S., Chiamori, N. and Abraham, G.E. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: Preliminary oral bioavailability and dose proportionality studies. Am. J. Obstet. Gynecol. 166: 1163-1168, 1992.
88. van Vollenhoven, R.F., Engleman, E.G. and McGuire, J.L. An open study of dehydroepiandrosterone in systemic lupus eryuiematosus. Arthritis Rheum. 37: 1305-1310, 1994.
89. Morales, A.J., Nolan, J.J., Nelson, J.C. and Yen, S.S.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78: 1360-1367, 1994.
90. Casson, P.R., Andersen, R.N., Herrod, H.G., Stentz, F.B., Straughn, A.B., Abraham, G.E. and Buster, J.E. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am. J. Obstet. Gynecol. 169: 1536-1539, 1993.
91. Pashko, L.L., Lewbart, M.L. and Schwartz, A.G. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted skin tumor formation by 16α-fluoro-5-androsten-17-one and its reversal by deoxyribonucleosides. Carcinogenesis 12: 2189-2192, 1991.
92. You, W.-C., Blot, W.J., Chang, Y.-S., Ershow, A., Yang, Z.T., An, Q., Henderson, B.E., Fraumeni, J.F. Jr. and Wang, T.-G. Allium vegetables and reduced risk of stomach cancer. J. Natl. Cancer Inst. 81: 162-164, 1989.
93. Wargovich, M.J. Inhibition of gastrointestinal cancer by organosulfur compounds in garlic. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992, 195-203.
94. Buiatti, E., Palli, D., Decarli, A., Amadori, D., Avellini, C., Bianchi, S., Bisemi, R., Cipriani, F., Cocco, P., Giacosa, A., Mambini, E., Puntoni, R., Vindigni, C., Fraumeni, J., Jr. and Blot, W. A case-control study of gastric cancer and diet in Italy. Int. J. Cancer 44: 611-616, 1989.
95. Belman, S. Onion and garlic oils inhibit tumor promotion. Carcinogenesis 4: 1063-1065, 1983.
96. Hussain, S.P., Jannu, L.N. and Rao, A.R. Chemopreventive action of garlic on methylcholanthrene-induced carcinogenesis in the uterine cervix of mice. Cancer Lett. 49: 175-180, 1990.
97. Wargovich, M.J. Diallyl sulfide, a flavor component of garlic (Allium sativum), inhibits dimethylhydrazine-induced colon cancer. Carcinogenesis 8: 487-489, 1987.
98. Spamins, V.L., Barany, G. and Wattenberg, L.W. Effects of organosulfur compounds from garlic and onions on benzo[a]pyrene-induced neoplasia and glutathione 5-transferase activity in the mouse. Carcinogenesis 9: 131-134, 1988.
99. Wattenberg, L.W., Sparnins, V.L. and Barany, G. Inhibition of N-nitrosodiethylamine Carcinogenesis in mice by naturally occurring organosulfur compounds and monoterpenes. Cancer Res. 49: 2689-2692, 1989.
100. Athar, M., Raza, H., Bickers, D.R. and Mukhtar, H. Inhibition of benzoyl peroxide-mediated tumor promotion in 7,12-dimethylbenz(a)anthracene-initiated skin of sencar mice by antioxidants nordihydroguaiaretic acid and diallyl sulfide. J. Invest. Dermatol. 94: 162-165, 1990.
101. Wargovich, M.J., Woods, C., Eng, V.W.S., Stephens, L.C. and Gray, K. Chemoprevention of N-nitrosomethylbenzylamine-induced esophageal cancer in rats by the naturally occurring thioether, diallyl sulfide. Cancer Res. 48: 6872-6875, 1988.
102. Hu, P.-J. and Wargovich, M.J. Effect of diallyl sulfide on MNNG-induced nuclear aberrations and ornithine decarboxylase activity in the glandular stomach mucosa of the Wistar rat. Cancer Lett. 47: 153-158, 1989.
103. Sumiyoshi, H. and Wargovich, M.J. Chemoprevention of 1,2-dimethylhydrazine-induced colon cancer in mice by naturally occurring organosulfur compounds. Can cer Res. 50: 5084-5087, 1990.
104. Brady, J.F., Li, D., Ishizaki, H. and Yang, C.S. Effect of diallyl sulfide on rat liver microsomal nitrosamine metabolism and other monooxygenase activities. Cancer Res. 48: 5937-5940, 1988.
105. Takayasu, J., Nishino, H. and Iwashima, A. Antitumor-promoting activity of curcumin. Proc. Annu. Meet. Jpn. Cancer Assoc. 46: 60, 1987.
106. Huang, M.-T., Smart, R.C., Wong, C-Q. and Conney, A.H. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48: 5941-5946, 1988.
107. Soudamini, K.K. and Kuttan, R. Inhibition of chemical carcinogenesis by curcumin. J. Ethnopharmacol. 27: 227-233, 1989.
108. Huang, M.-T., Lysz, T., Ferraro, T. and Conney, A.H. Inhibitory effects of curcumin on tumor promotion in mouse epidermis. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992, pp. 375-391.
109. Srimal, R.C. and Dhawan, B.N. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J. Pharm. Phamacol. 25: 447- 452, 1973.
110. Rao, T.S., Basu, N. and Siddiqui, H.H. Anti-inflammatory activity of curcumin analogues. Indian J. Med. Res. 75: 574-578, 1982.
111. Mukhopadhyay, A., Basu, N., Ghatak, N. and Gujral, P.K. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 12: 508-515, 1982.
112. Kelloff, G.J., Crowell, J.A., Hawk, E.T., Steele, V.E., Lubet, R.A., Boone, C.W., Covey, J.M., Doody, L.A., Omenn, O.S., Greenwald, P., Hong, W.K., Parkinson, D.R., Bagheri, D., Baxter, G.T., Blunden, M., Doeltz, M.K., Eisenhauer, K.M., Johnson, K., Longfellow, D.G., Knapp, G.G., Malone, W.F., Nayfield, S.G., Seifried, H.E., Swall, L.M. and Sigman, C.C. Clinical development plan: Curcumin. J. Cell. Biochem. Suppl. 26, 1996 (this volume).
113. Huang, M.-T., Lysz, T., Ferraro, T., Abidi, T.F., Laskin, J.D. and Conney, A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 51: 813-819, 1991.
114. Sharma, O.P. Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol 25: 1811-1812, 1976.
115. Toda, S., Miyase, T., Arichi, H., Tanizawa, H. and Takino, Y. Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L.. Chem. Pharm. Bull. 33: 1725-1728, 1985.
116. Srivastava, R. Inhibition of neutrophil response by curcumin. Agents Actions 28: 298-303, 1989.
117. Azuine, M.A., Kayal, J.J. and Bhide, S.V. Protective role of aqueous turmeric extract against mutagenicity of direct-acting carcinogens as well as benzo[a]pyrene-induced genotoxicity and carcinogenicity. J. Cancer Res. Clin. Oncol. 118: 447-452, 1992.
118. Reddy, A.C.P. and Lokesh, B.R. Alterations in lipid peroxides in rat liver by dietary n-3 fatty acids: Modulation of antioxidant enzymes by curcumin, eugenol, and vitamin E. J. Nutr. Biochem. 5: 181-188, 1994.
119. Susan, M. and Rao, M.N.A. Induction of glutathione S-transferase activity by curcumin in mice. Arzneimittelforschung 42-2: 962-964, 1992.
120. Nagabhushan, M. and Bhide, S.V. Nonmutagenicity of curcumin and its antimutagenic action versus chili and capsaicin. Nutr. Cancer 8: 201-210, 1986.
121. Nagabhushan, M., Amonkar, A.J. and Bhide, S.V. In vitro antimutagenicity of curcumin against environmental mutagens. Food Chem. Toxicol 25: 545-547, 1987.
122. Mulky, N., Amonkar, AJ. and Bhide, S.V. Antimutagenicity of curcumins and related compounds: The structural requirement for the antimutagenicity of curcumins. Indian Drugs 25: 91-95, 1987.
123. Kanerva, R.L., Ridder, G.M., Lefever, F.R. and Alden, C.L. Comparison of short-term renal effects due to oral administration of decalin or d-limonene in young adult male Fischer-344 rats. Food Chem. Toxicol. 25: 345- 353, 1987.
124. Abraham, S.K., Sarma, L. and Kesavan, P.C. Protective effects of chlorogenic acid, curcumin and β-carotene against γ-radiation-induced in vivo chromosomal damage. Mutat. Res. 303: 109-112, 1993.
125. Lahiri, M., Maru, G.B. and Bhide, S.V. Effect of plant phenols, β-carotene and α-tocopherol on benzo[a] pyrene-induced DNA damage in the mouse forestomach mucosa (target organ) and bone marrow polychromatic erythrocytes (non-target organ). Mutat. Res. 303: 97-100, 1993.
126. Huang, T.S., Lee, S.C. and Lin, J.K. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 88: 5292-5296, 1991.
127. Kakar, S.S. and Roy, D. Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin. Cancer Lett. 87: 85-89, 1994.
128. Liu, J.-Y., Lin, S.-J., and Lin, J.-K. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14: 857-861, 1993.
129. Lu, Y.-P., Chang, R.L., Huang, M.-T. and Conney, A.H. Inhibitory effect of curcumin on 12-O-tetradecanoyl phorobol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 14: 293-297, 1993.
130. Korutla, L. and Kumar, R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta 1224: 597-600, 1994.
131. Korutla, L., Cheung, J.Y., Mendelsohn, J. and Kumar, R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 16: 1741-1745, 1995.
132. Stoner, G.D. and Mukhtar, H. Polyphenols as cancer chemopreventive agents. J. Cell. Biochem. 22: 169-180, 1995.
133. Ammon, H.P.T. and Wahl, M.A. Pharmacology of Curcuma longa. Planta Med. 57: 1-7, 1991.
134. Mazumder, A., Raghavan, K., Weinstein, J., Kohn, K.W. and Pommier, Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem. Pharmacol. 49: 1165-1170, 1995.
135. HSDB Hazardous Substances Data Bank. Available online via National Library of Medicine (NLM). Latest update, Jan., 1995.
136. Gupta, B., Kulshrestha, V.K., Srivastava, R.K. and Prasad, D.N. Mechanisms of curcumin induced gastric ulcer in rats. Indian J. Med. Res. 71: 806-814, 1980.
137. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: DHEA analog 8354. J. Cell. Biochem. 20: 141-146, 1994.
138. Ratko, T.A., Detrisac, C.J., Mehta, R.G., Kelloff, G.J. and Moon, R.C. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res. 51: 481-486, 1991.
139. Naim, M., Gestetner, B., Kirson, I., Birk, Y. and Bondi, A. A new isoflavone from soya beans. Phytochemistry 12: 169-170, 1973.
140. Bradbury, R.B. and White, D.E. The chemistry of subterranean clover. Part I. Isolation of formononetin and genistein. J. Chem. Soc. 4: 3447-3449, 1951.
141. Bickoff, E.M., Livingston, A.L., Hendrickson, A.P. and Booth, A.N. Relative potencies of several estrogen-like compounds found in forages. J. Agric. Food Chem. 10: 410-412, 1962.
142. Setchell, K.D.R. Naturally occurring non-steroidal estrogens of dietary origin. In: McLachlan, J.A. (ed.) Estrogens in the Environment. New York: Elsevier Science Publishing Co., Inc., 1985, pp. 69-85.
143. Rosenblum, E.R., Campbell, I.M., Van Thiel, D.H. and Gavaler, J.S. Isolation and identification of phytoestrogens from beer. Alcohol. Clin. Exp. Res. 16: 843-845, 1992.
144. Wang, H. and Murphy, P.A. Isoflavone content in commercial soybean foods. J. Agric. Food Chem. 42: 1666-1673, 1994.
145. Adlercreutz, H., Markkanen, H. and Watanabe, S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342: 1209-1210, 1993.
146. Adlercreutz, H., Fotsis, T., Bannwart, C., Wahala, K., Brunow, G. and Hase, T. Isotope dilution gas chromatographic-mass spectrometric method for the determination of lignans and isoflavonoids in human urine, including identification of genistein. Clin. Chim. Acta 199: 263-278, 1991.
147. Adlercreutz, H., Honjo, H., Higashi, A., Fotsis, T., Hamalainen, E., Hasegawa, T. and Okada, H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 54: 1093-1100, 1991.
148. Baggott, J.E., Ha, T., Vaughn, W.H., Juliana, M.M., Hardin, J.M. and Grubbs, C.J. Effect of miso (Japanese soybean paste) and NaCl on DMBA-induced rat mammary tumors. Nutr. Cancer 14: 103-109, 1990.
149. Barnes, S., Grubbs, C., Setcheil, K.D.R. and Carlson, J. Soybeans inhibit mammary tumors in models of breast cancer. Prog. Clin. Biol. Res. 347: 239-253, 1990.
150. Messina, M.J., Persky, V., Setcheil, K.D.R. and Barnes, S. Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr. Cancer 21: 113-131, 1994.
151. Troll, W., Wiesner, R., Shellabarger, C.J., Holtzman, S. and Stone, J.P. Soybean diet lowers breast tumor incidence in irradiated rats. Carcinogenesis 1: 469-472, 1980.
152. Hawrylewicz, E.J., Huang, H.H. and Blair, W.H. Dietary soybean isolate
153. Pereira, M.A., Barnes, L.H., Rassman, V.L., Kelloff, G.J. and Steele, V.E. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15: 1049-1054, 1994.
154. Steele, V.E., Pereira, M.A., Sigman, C.C. and Kelloff, G.J. Cancer chemoprevention agent development strategies for genistein. J. Nutr. 125: 713S-716S, 1995.
155. Reddy, B.S., Wang, C.-X., Aliaga, C., Rao, C.V., Lubet, R.A., Steele, V.E. and Kelloff, G.J. Potential chemopreventive activity of perillyl alcohol and enhancement of experimental colon carcinogenesis by folic acid and genistein. Proc. Annu. Meet. Am. Assoc. Cancer Res. 37: 271, abstract no. 1849, 1996.
156. Shutt, D.A. and Cox, R.I. Steroid and phyto-oestrogen binding to sheep uterine receptors in vitro. J. Endocrinol. 52: 299-310, 1972.
157. Verdeal, K., Brown, R.R., Richardson, T. and Ryan, D.S. Affinity of phytoestrogens for estradiol-binding proteins and effect of coumestrol on growth of 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors. J. Natl. Cancer Inst. 64: 285-290, 1980.
158. Kvetnansky, R., Sun, C.L., Lake, C.R., Thoa, N., Torda, T. and Kopin, I.J. Effect of handling and forced immobilization on rat plasma levels of epinephrine, norepinephrine, and dopamine-β-hydroxylase. Endocrinology 103: 1868-1874, 1978.
159. Cheng, E., Story, C.D., Yoder, L., Hale, W.H. and Burroughs, W. Estrogenic activity of isoflavone derivatives extracted and prepared from soybean oil meal. Science 118: 164-165, 1953.
160. Folman, Y. and Pope, G.S. The interaction in the immature mouse of potent oestrogens with coumestrol, genistein and other utero-vaginotrophic compounds of low potency. J. Endocrinol. 34: 215-225, 1966.
161. Markiewicz, L., Garey, J., Adlercreutz, H. and Gurdipe, E. In vitro bioassays of non-steroidal phytoestrogens. J. Steroid Biochem Mol. Biol. 45: 399-405, 1993.
162. Makishima, M., Honma, Y., Hozumi, M., Sampi, K., Hattori, M., Umezawa, K. and Motoyoshi, K. Effects of inhibitors of protein tyrosine kinase activity and/or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells.Leuk.Res, 15:701-708, 1991.
163. Lamartiniere, C.A., Moore, J.B., Brown, N.M., Thompson, R., Hardin, M.J. and Barnes, S. Genistein suppresses mammary cancer in rats. Carcinogenesis 16: 2833-2840, 1995.
164. Upadhyaya, P. and El-Bayoumy, K. Effects of dietary soy protein isolate and genistein on the levels of 7,12-dimethyl-benz(a)anthracene (DMBA)-DNA binding in mammary glands of female CD rats. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36: 597, abstract no. 3553, 1995.
165. Constantinou, A., Thomas, C., Mehta, R., Runyan, C. and Moon, R. The effect of genistein and daidzein on MNU-induced mammary tumors in rats. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36: 115, abstract no. 684, 1995.
166. Henderson, B.E., Ross, R. and Bernstein, L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res. 48: 246-253, 1988.
167. Wang, T.T.Y., Sathyamoorthy, N. and Phang, J.M. Differential effects of genistein on pS2 expression and proliferation in MCF-7 cells are concentration-dependent. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 84, abstract no. 503, 1994.
168. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S.-I., Itoh, N., Shibuya, M. and Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262: 5592-5595, 1987.
169. Sibley, D.R., Benovic, J.L., Caron, M.G. and Lefkowitz, R.J. Regulation of transmembrane signaling by receptor phosphorylation. Cell 48: 913-922, 1987.
170. Peterson, G. and Barnes, S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 22: 335-345, 1993.
171. Kiguchi, K., Constantinou, A.I. and Huberman, E. Genistein-induced cell differentiation and protein-linked DNA strand breakage in human melanoma cells. Cancer Commun. 2: 271-278, 1990.
172. Chang, C.-J. and Geahlen, R.L. Protein-tyrosine kinase inhibition: Mechanism-based discovery of antitumor agents. J. Nat. Prod. 55: 1529-1560, 1992.
173. Dean, N.M., Kanemitsu, M. and Boynton, A.L. Effects of the tyrosine-kinase inhibitor genistein on DNA synthesis and phospholipid-derived second messenger generation in mouse 10T1/2 fibroblasts and rat liver T51B cells. Biochem. Biophys. Res. Commun. 165: 795- 801, 1989.
174. Zwiller, J., Sassone-Corsi, P., Kakazu, K. and Boynton, A.L. Inhibition of PDGF-induced c-jun and c-fos expression by a tyrosine protein kinase inhibitor. Oncogene 6: 219-221, 1991.
175. Nakafuku, M., Satoh, T. and Kaziro, Y. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active ras-GTP complex in rat pheochromocytoma PC12 cells. J. Biol. Chem. 267: 19448-19454, 1992.
176. Honma, Y., Okabe-Kado, J., Kasukabe, T., Hozumi, M. and Umezawa, K. Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells. Jpn. J. Cancer Res. 81: 1132-1136, 1990.
177. Fotsis, T., Pepper, M., Adlercreutz, H., Fleischmann, G., Hase, T., Montesano, R. and Schweigerer, L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. USA 90: 2690-2694, 1993.
178. Coyne, D.W. and Monison, A.R. Effect of the tyrosine kinase inhibitor, genistein, on interleukin-1 stimulated PGE2 production in mesangial cells. Biochem. Biophys. Res. Commun. 173: 718-724, 1990.
179. Glaser, K.B., Sung, A., Bauer, J. and Weichman, B.M. Regulation of eicosanoid biosynthesis in the macrophage. Involvement of protein tyrosine phosphorylation and modulation by selective protein tyrosine kinase inhibitors. Biochem. Pharmacol. 45: 711-721, 1993.
180. Takano, T., Takada, K., Tada, H., Nishiyama, S. and Amino, N. Genistein, a tyrosine kinase inhibitor, blocks the cell cycle progression but not Ca2+ influx induced by BAY K8644 in FRTL-5 cells. Biochem. Biophys. Res. Commun. 190: 801-807, 1993.
181. Majumdar, A.P.N. Role of tyrosine kinases in gastrin induction of ornithine decarboxylase in colonic mucosa. Am. J. Physiol 259: G626-G630, 1990.
182. Atluru, S. and Atluru, D. Evidence that genistein, a protein-tyrosine kinase inhibitor, inhibits CD28 monoclonal-antibody-stimulated human T cell proliferation. Transplantation 51: 448-450, 1991.
183. Katagiri, K., Katagiri, T., Kajiyama, K., Uehara, Y., Yamamoto, T. and Yoshida, T. Modulation of monocytic differentiation of HL-60 cells by inhibitors of protein tyrosine kinases. Cell. Immunol. 140: 282-294, 1992.
184. Chae, Y.-H., Marcus, C.B., Ho, D.K., Cassady, J.M. and Baird, W.M. Effects of synthetic and naturally occurring flavonoids on benzo[a]pyrene metabolism by hepatic microsomes prepared from rats treated with cytochrome P-450 inducers. Cancer Lett. 60: 15-24, 1991.
185. Lee, H., Wang, H.-W., Su, H.-Y. and Hao, N.J. The structure-activity relationships of flavonoids as inhibitors of cytochrome P-450 enzymes in rat liver microsomes and the mutagenicity of 2-amino-3-methyl-imidazo[4,5-f]quinoline. Mutagenesis 9: 101-106, 1994.
186. Wei, H., Wei, L., Frenkel, K., Bowen, R. and Barnes, S. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr. Cancer 20: 1-12, 1993.
187. Wei, H. Isoflavones scavenge reactive oxygen species and protect DNA bases from oxidative DNA damage. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 619, abstract no. 3690, 1994.
188. Wei, H., Cai, Q. and Rahn, R.O. Inhibition of UV light- and Fenton reaction-induced oxidative DNA damage by the soybean isoflavone genistein. Carcinogenesis 17: 73-77, 1996.
189. Okura, A., Arakawa, H., Oka, H., Yoshinari, T. and Monden, Y. Effect of genistein on topoisomerase activity and on the growth of [VAL 12] Ha-ras-transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun, 157: 183-189, 1988.
190. Finlay, G.J., Holdaway, K.M. and Baguley, B.C. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. Oncol. Res. 6: 33-37, 1994.
191. Matsukawa, Y., Marui, N., Sakai, T., Satomi, Y., Yoshida, M., Matsumoto, K., Nishino, H. and Aoike, A. Genistein arrests cell cycle progression at G2-M. Cancer Res. 53: 1328-1331, 1993.
192. McCabe, M.J., Jr. and Orrenius, S. Genistein induces apoptosis in immature human thymocytes by inhibiting topoisomerase-II. Biochem. Biophys. Res. Commun. 194: 944-950, 1993.
193. Yanagihara, K., Ito, A., Toge, T. and Numoto, M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res. 53: 5815-5821, 1993.
194. Spinozzi, F., Pagliacci, M.C., Migliorati, G., Moraca, R., Grignani, F., Riccardi, C. and Nicoletti, I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res. 18: 431-439, 1994.
195. Mamett, L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52: 5575-5589, 1992.
196. Hixson, L.J., Alberts, D.S., Krutzsch, M., Einsphar, J., Brendel, K., Gross, P.M., Paranka, N.S., Baier, M., Emerson, S., Pamukcu, R. and Burt, R. W. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev. 3: 433-438, 1994.
197. Bradfield, C.A. and Bjeldanes, L.F. High-performance liquid chromatographic analysis of anticarcinogenic indoles in Brassica oleracea. J. Agric. Food Chem. 35: 46-49, 1987.
198. Young, T.B., Wolf, D.A. Case-control study of proximal and distal colon cancer and diet in Wisconsin. Int. J. Cancer 42: 167-175, 1988.
199. Sparnins, V.L., Venegas, P.L. and Wattenberg, L.W. Glutathione 5-transferase activity: Enhancement by compounds inhibiting chemical carcinogenesis and by dietary constituents. J. Natl. Cancer Inst. 68: 493-496, 1982.
200. Salbe, A.D. and Bjeldanes, L.F. Dietary influences on rat hepatic and intestinal DT-diaphorase activity. Food Chem. Toxicol. 24: 851-856, 1986.
201. Wortelboer, H.M., van der Linden, E.C.M., de Kruif, C.A., Noordhoek, J., Blaauboer, B.J., van Bladeren, P.J. and Falke, H.E. Effects of indole-3-carbinol on biotransformation enzymes in the rat: In vivo changes in liver and small intestinal mucosa in comparison with primary hepatocyte cultures. Food Chem. Toxicol. 30: 589-599, 1992.
202. 1 in the rat. Drug Metab. Dispos. 22: 383-391, 1994.
203. 1 exo-epoxide - Association with reduced levels of hepatic aflatoxin-DNA adducts in vivo. Drug Metab. Dispos. 22: 392-399, 1994.
204. Wattenberg, L.W. and Loub, W.D. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res. 38: 1410-1413, 1978.
205. Morse, M.A., LaGreca, S.D., Amin, S.G. and Chung, F.-L Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosarnino)-1-(3-pyridyl)-1-butanone(NNK) and on the metabolism and disposition of NNK in A/J mice. Cancer Res. 50: 2613-2617, 1990.
206. 1 activation. Biochem. Pharmacol. 39: 19-26, 1990.
207. Wattenberg, L.W. Chemoprevention of cancer. Cancer Res. 45: 1-8, 1985.
208. Grubbs, C.J., Steele, V.E., Casebolt, T., Juliana, M.M., Eto, I., Whitaker, L.M., Dragnev, K.H., Kelloff, G.J. and Lubet, R.L. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res. 15: 709-716, 1995.
209. Bradfield, C.A. and Bjeldanes, L.F. Structure-activity relationships of dietary indoles: A proposed mechanism of action as modifiers of xenobiotic metabolism. J. Toxicol. Environ. Health} 21: 311-323, 1987.
210. Bjeldanes, L.F., Kim, J.-Y., Grose, K.R., Bartholomew, J.C. and Bradfield, C.A. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: Comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. USA 88: 9543-9547, 1991.
211. Park, J.-Y. and Bjeldanes, L.F. Organ-selective induction of cytochrome P-450-dependent activities by indole-3-carbinol-derived products: Influence on covalent binding of benzo[a]pyrene to hepatic and pulmonary DNA in the rat. Chem. Biol. Interact. 83: 235-247, 1992.
212. Dashwood, R.H., Fong, A.T., Arbogast, D.N., Bjeldanes, L.F., Hendricks, J.D. and Bailey, G.S. Anticarcinogenic activity of indole-3-carbinol acid products: Ultrasensitive bioassay by trout embryo microinjection. Cancer Res. 54: 3617-3619, 1994.
213. De Kruif, C.A., Marsman, J.W., Venekamp, J.C., Falke, H.E., Noordhoek, J., Blaauboer, B.J. and Wortelboer, H.M. Structure elucidation of acid reaction products of indole-3-carbinol: Detection in vivo and enzyme induction in vitro. Chem. Biol. Interact. 80: 303-315, 1991.
214. Bradlow, H.L., Michnovicz, J.J., Telang, N.T. and Osborne, M.P. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12: 1571-1574, 1991.
215. Kojima, T., Tanaka, T. and Mori, H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res. 54: 1446-1449, 1994.
216. Guyton, A.C. (ed.) Textbook of Medical Physiology, 8th ed., Philadelphia, PA: W.B. Saunders Company, p. 905, 1991.
217. Schneider, J., Kinne, D., Fracchia, A., Pierce, V., Anderson, K.E., Bradlow, H.L. and Fishman, J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc. Natl. Acad. Sci. USA 79: 3047-3051, 1982.
218. Bradlow, H.L., Hershcopf, R.J., Martucci, C.P. and Fishman, J. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: A possible model for the hormonal etiology of breast cancer in humans. Proc. Natl. Acad. Sci. USA 82: 6295-6299, 1985.
219. Swaneck, G.E. and Fishman, J. Estrogen actions on target cells: Evidence for different effects by products of two alternative pathways of estradiol metabolism. In: Hochberg, R.B. and Naftolin, F. (eds.) The New Biology of Steroid Hormones, New York, NY: Raven Press, 1991, 45-70.
220. Bradlow, H.L., Michnovicz, J.J., Halper, M., Miller, D.G., Wong, G.Y.C. and Osborne, M.P. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol. Biomarkers Prev. 3: 591-595, 1994.
221. Lubet, R.A., Beebe, L., Bjeldanes, L., Bradlow, L.H., Kelloff, G.J., Steele, V.E., Eto, I. and Grubbs, C.J. Chemopreventive effects of indole-3-carbinol (3IC) on MNU induced mammary cancer in Sprague Dawley rats. Proc. Annu. Meet. Am. Assoc. Cancer Res. 37: 277, abstract no. 1890, 1996.
222. Tanaka, T., Mori, Y., Morishita, Y., Kara, A., Ohno, T., Kojima, T. and Mori, H. Inhibitory effect of sinigrin and indole-3-carbinol on diethylnitrosamine-induced hepatocarcinogenesis in male ACI/N rats. Carcinogenesis 11: 1403-1406, 1990.
223. Tanaka, T., Kojima, T., Morishita, Y. and Mori, H. Inhibitory effects of the natural products indole-3-carbinol and sinigrin during initiation and promotion phases of 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Jpn. J. Cancer Res. 83: 835-842, 1992.
224. Karp, F., Mihaliak, C.A., Harris, J.L. and Croteau, R. Monoterpene biosynthesis: Specificity of the hydroxylations of (-)-limonene by enzyme preparations from peppermint (Mentha piperita), spearmint (Mentha spicaia), and perilla (Perilla frutescens) leaves. Arch. Biochem. Biophys. 276: 219-226, 1990.
225. Thapa, R.K., Bradu, B.L., Vashist, V.N. and Atal, C.K. Screening of Cymbopogon species for useful constituents.. Flavour Ind. 2: 49-51, 1971.
226. Opdyke, D.L.J. Monograph on fragrance raw materials. Food Cosmet. Toxicol. 19: 237-254, 1981.
227. Crowell, P.L., Lin, S., Vedejs, E. and Gould, M.N. Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth. Cancer Chemother. Pharmacol 31: 205-212, 1992.
228. Crowell, P.L., Chang, R.R., Ren, Z., Elson, C.E. and Gould, M.N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J. Biol. Chem. 266: 17679-17685, 1991.
229. Haag, J.D., Crowell, P.L. and Gould, M.N. Enhanced inhibition of protein isoprenylation and tumor growth by perillyl alcohol, an hydroxylated analog of d-limonene. Proc. Annu. Meet. Am. Assoc. Cancer Res. 33: 524, abstract no. 3135, 1992.
230. Crowell, P.L., Ren, Z., Lin, S., Vedejs, E. and Gould, M.N. Structure-activity relationships among monoterpene, inhibitors of protein isoprenylation and cell proliferation. Biochem. Pharmacol. 47: 1405-1415, 1994.
231. Ren, Z. and Gould, M.N. Inhibition of protein isoprenylation by the monoterpene perillyl alcohol in intact cells and in cell lysates. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36: 585, abstract no. 3484, 1995.
232. Gelb, M.H., Tamanoi, F., Yokoyama, K., Ghomashchi, F., Esson, K. and Gould, M.N. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett. 91: 169-175, 1995.
233. Hohl, R.J. and Lewis, K. Differential effects of monoterpenes and lovastatin on RAS processing. J. Biol. Chem. 270: 17508-17512, 1995.
234. Ren, Z. and Gould, M.N. Inhibition of ubiquinone and cholesterol synthesis by the monoterpene perillyl alcohol. Cancer Lett. 76: 185-190, 1994.
235. Bronfen, J.H., Stark, M.J. and Crowell, P.L. Inhibition of human pancreatic carcinoma cell proliferation by perillyl alcohol. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 431, abstract no. 2572, 1994.
236. Cerda, S., Wilkinson, J., IV and Broitman, S.A. Enhanced antitumor activity of lovastatin and peryllyl alcohol combinations in the colonic adenocarcinoma cells line SW480. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 335, abstract no. 1996, 1994.
237. Ruch, R.J. and Sigler, K. Growth inhibition of rat liver epithelial tumor cells by monoterpenes does not involve ras plasma membrane association. Carcinogenesis 15: 787-789, 1994.
238. Gould, M.N. Prevention and therapy of mammary cancer by monoterpenes. J. Cell. Biochem. 22: 139-144, 1995.
239. Shi, W. and Gould, M.N. Differentiation of neuro-2a cells induced by the monoterpene, perillyl alcohol. Proc. Annu. Meet. Am. Assoc. Cancer Res. 34: 548, abstract no. 3264, 1993.
240. Mills, J.J., Chan, R.S., Boyer, I.J., Gould, M.N. and Jirtle, R.L. Induction of apoptosis in liver tumors by the monoterpene peritlyl alcohol. Cancer Res. 55: 979-983, 1995.
241. Alison, M. Promoting apoptosis. Hum. Exp. Toxicol. 14: 697-698, 1995.
242. Ariazi, E.A. and Gould, M.N. Identification of induced/ repressed genes in monoterpene-treated regressing rat mammary carcinomas using subtractive display. Proc. Annu. Meet. Am. Assoc. Cancer Res. 37: 398-399, 1996.
243. 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res. 53: 3849-3852, 1993.
244. Gould, M.N. Chemoprevention of mammary cancer by monoterpenes. Proc. Annu. Meet. Am. Assoc. Cancer Res. 34: 572-573, 1993.
245. Jeffers, L., Church, D., Gould, M. and Wilding, G. The effect of perillyl alcohol on the proliferation of human prostatic cell lines. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36: 303, abstract no. 1800, 1995.
246. Stark, M.J., Burke, Y.D., McKinzie, J.H., Ayoubi, A.S. and Crowell, P.L. Chemotherapy of pancreatic cancer with the monoterpeneperillyl alcohol. Cancer Lett. 96: 15-21, 1995.
247. Haag, J.D. and Gould, M.N. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother. Pharmacol. 34: 477-483, 1994.
248. van Duuren, B.L. and Goldschmidt, B.M. Cocarcinogenic and tumor-promoting agents in tobacco carcinogenesis. J. Natl. Cancer Inst. 56: 1237-1242, 1976.
249. Maltzman, T.H., Hurt, L.M., Elson, C.E., Tanner, M.A. and Gould, M.N. The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange oil. Carcinogenesis 10: 781-783, 1989.
250. Gould, M.N. Chemoprevention and treatment of experimental mammary cancers by limonene. Proc. Annu. Meet. Am. Assoc. Cancer Res. 32: 474-475, 1991.
251. Gould, M.N. The introduction of activated oncogenes to mammary cells in vivo using retroviral vectors: A new model for the chemoprevention of premalignant lesions of the breast. J. Cell. Biochem. 17G: 66-72, 1993.
252. Gould, M.N., Moore, C.J., Zhang, R., Wang, B.C., Kennan, W.S. and Haag, J.D. Limonene chemoprevention of mammary carcinoma induction following direct in situ transfer of v-Ha-ras. Cancer Res. 54: 3540-3543, 1994.
253. Jirtle, R.L. and Gould, M.N. Chemoprevention of hepatocellular carcinomas by the monoterpene, perillyl alcohol. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 626, abstract no. 3732, 1994.
254. Elegbede, J.A., Elson, C.E., Tanner, M.A., Qureshi, A. and Gould, M.N. Regression of rat primary mammary tumors following dietary d-limonene. J. Natl. Cancer Inst. 76: 323-325, 1986.
255. Haag, J.D., Lindstrom, M.J. and Gould, M.N. Limonene-induced regression of mammary carcinomas. Cancer Res. 52: 4021-4026, 1992.
256. Spence, R.-M.M. and Tucknott, O.G. An apparatus for the comparative collection of headspace volatiles of watercress. J. Sci. Food Agric. 34: 412-416, 1983.
257. Chung, F.-L., Morse, M. A, Eklind, K.I. and Lewis, J. Quantitation of human uptake of the anticarcinogen phenethyl isothiocyanate after a watercress meal. Cancer Epidemiol. Biomarkers Prev. 1: 383-388, 1992.
258. Lichtenstein, E.P., Strong, F.M. and Morgan, D.G. Identification of 2-phenylethylisothiocyanate as an insecticide occurring naturally in the edible part of turnips. J. Agric. Food Chem. 10: 30-33, 1962.
259. Tookey, H.L., VanEtten, C.H. and Daxenbichler, M.E. Glucosinolates. In: Liener, I.E. (ed.) Toxic Constituents of Plant Foodstuffs. 2nd ed., New York: Academic Press, Chap. 4, 1980, pp. 103-142.
260. Buttery, R.G., Guadagni, D.G., Ling, L.C., Seifert, R.M. and Lipton, W. Additional volatile components of cabbage, broccoli, and cauliflower. J. Agric. Food Chem. 24: 829-832, 1976.
261. Daxenbichler, M.E., VanEtten, C.H. and Spencer, G.F. Glucosinolates and derived products in cruciferous vegetables. Identification of organic nitriles from cabbage. J. Agric. Food Chem. 25: 121-124, 1977.
262. Abraham, V. and Deman, J.M. Determination of volatile sulfur compounds in canola oil. J. Am. Oil Chem. Soc. 62: 1025-1028, 1985.
263. Morse, M.A., Amin, S.G., Hecht, S.S. and Chung, F.-L. Effects of aromatic isothiocyanates on tumorigenicity, O6-methylguanine formation, and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res. 49: 2894-2897, 1989.
264. Morse, M.A., Eklind, K.I., Amin, S.G., Hecht, S.S. and Chung, F-L. Effects of alkyl chain length on the inhibition of NNK-induced lung neoplasia in A/J mice by arylalkyl isothiocyanates. Carcinogenesis 10: 1757-1759, 1989.
265. Morse, M.A., Hecht, S.S. and Chung, F.L. Inhibition of tobacco-specific nitrosamine 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumors and DNA methylation in F344 rats and A/J mice by phenethyl isothiocyanate. Basic Life Sci. 52: 345-350, 1990.
266. Morse, M.A., Eklind, K.I., Hecht, S.S., Jordan, K.G., Choi, C., Desai, D.H., Amin, S.G. and Chung, F.-L. Structure-activity relationships for inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone lung tumorigenesis by arylalkyl isothiocyanates in A/J mice. Cancer Res. 51: 1846-1850, 1991.
267. Morse, M.A., Eklind, K.J., Amin, S.G. and Chung, F.-L. Effect of frequency of isothiocyanate administration on inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary adenoma formation in A/J mice. Cancer Lett. 62: 77-81, 1992.
268. Stoner, G.D., Morrissey, D.T., Heur, Y.-H., Daniel, E.M., Galati, A.J. and Wagner, S.A. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethyl amine carcinogenesis in the rat esophagus. Cancer Res. 51: 2063-2068, 1991.
269. Morse, M.A., Zu, H.X., Galati, A.I., Schmidt, C.J. and Staner, G.D. Dose-related inhibition by dietary phenethyl isothiocyanate of esophageal tumorigenesis and DNA methylation induced by N-nitrosomethylbenzyl amine in rats. Cancer Lett. 72: 103-110, 1993.
270. Stoner, G.D., Galati, A.J., Schmidt, C.J. and Morse, M.A. Inhibition of esophageal tumorigenesis by phenethyl isothiocyanate. ACS Symp. Ser. 1994: 173-180, 1994.
271. Wattenberg, L.W. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J. Natl. Cancer Inst. 58: 395-398, 1977.
272. Mangelsdorf, D.J., Umesono, K. and Evans, R.M. The retinoid receptors. In: Sporn, M.B., Roberts, A.B. and Goodman, D.S. (eds.) The Retinoids: Biology, Chemistry, and Medicine, 2nd Edition. New York: Raven Press, 1994, pp. 319-349.
273. Heyman, R.A., Mangelsdorf, D.J., Dyck, J.A., Stein, R.B., Eichele, G., Evans, R.M. and Thaller, C. 9-cis-retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68: 397-406, 1992.
274. Anzano, M.A, Byers, S.W., Smith, J.M., Peer, C.W., Mullen, L.T., Brown, C.C., Roberts, A.B. and Sporn, M.B. Prevention of breast cancer in the rat with 9-cis- retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54: 4614-4617, 1994.
275. Anzano, M.A., Peer, C.W., Smith, J.M., Mullen, L.T., Shrader, M.W., Logsdon, D.L., Driver, C.J., Brown, C.C., Roberts, A.B. and Sporn, M.B. Chemoprevention of mammary carcinogenesis in the rat Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88: 123-125, 1996.
276. Kizaki, M., Ikeda, Y., Tanosaki, R., Nakajima, H., Morikawa, M., Sakashita, A. and Koeffler, H.P. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-α and retinoid X receptor-α RNA by HL-60 cells. Blood 82: 3592-3599, 1993.
277. Majewski, S., Szmurlo, A., Marczak, M., Jablonska, S. and Bollag, W. Synergistic effect of retinoids and interferon α on tumor-induced angiogenesis: Anti-angiogenic effect of HPV-harboring tumor-cell lines. Int. J. Cancer 57: 81-85, 1994.
278. Kurie, J.M., Buck, J., Eppinger, T.M., Moy, D. and Dmitrovsky, E. 9-cis and all-trans retinoic acid induce a similar phenotype in human teratocarcinoma cells. Differentiations 54: 123-129, 1993.
279. Han G., Chang, B. and Sidell, N. Comparison of effects of all-trans retinoic acid and 9-cis retinoic acid in inducing differentiation of human neuroblastoma cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 37, abstractno. 219, 1994.
280. Nagy, L., Thomazy, V.A., Shipley, G.L., Fesus, L., Lamph, W., Heyman, R.A., Chandraratna, R.A.S. and Davies, P.J.A. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell. Biol. 15: 3540-3551, 1995.
281. Cesario, R.M., McClurg, M.R., Wong, G.L., Sicurello, J.P., Heyman, R.A. and Lamph, W.W. Growth inhibition of multiple myeloma and squamous cell carcinoma by 9-cis retinoic acid. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 275, abstract no. 1645, 1994.
282. Rubin, M., Fenig, E., Rosenauer, A., Menendez-Botet, C., Achkar, C., Bentel, J.M., Yahalom, J., Mendelsohn, J. and Miller, W.H., Jr. 9-cis Retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res. 54: 6549-6556, 1994.
283. Schippers, I.J., Kloppenburg, M., Snippe, L. and Ab, G. 9-cis-Retinoic acid represses estrogen-induced expression of the very low density apolipoprotein II gene. Mol. Cell. Endocrinol. 105: 175-182, 1994.
284. Miller, V.A., Rigas, J.R., Benedetti, P.M., Verret, A.L., Tong, W.P., Kris, M.G., Gill, G.M., Loewen, G.R., Truglia, J.A., Ulm, E.H. and Warrell, R.P., Jr. Initial clinical trial of the retinoid receptor pan agonist 9-cis- retinoic acid. Clin. Cancer Res. 2: 471-475, 1996.
285. Miller, W.H., Jr., Jakubowski, A., Tong, W.P., Miller, V.A., Rigas, J.R., Benedetti, F., Gill, G.M., Truglia, J. A., Ulm, E., Shirley, M. and Warrell, R.P., Jr. 9-cis- Retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85: 3021-3027, 1995.
286. Kurie, J.M., Lee, J.S., Griffin, T., Lippman, S.M., Drum, P., Thomas, M.P., Weber, C., Bader, M., Massimini, G. and Hong, W.K. Phase I trial of 9-cis- retinoic acid in adults with solid tumors. Clin. Cancer Res. 2: 287-293, 1996.
287. Sass, J.O., Masgrau, E., Saurat, J.-H. and Nau, H. Metabolism of oral 9-cis retinoic acid in the human. Identification of 9-cis-retinoyl-β-glucuronide and 9-cis- 4-oxo-retinoyl-β-glucuronide as urinary metabolites. Drug Metab. Dispos. 23: 887-891, 1995.
288. Alberts, D.S., Hixson, L., Ahnen, D., Bogert, C., Einspahr, J., Paranka, N., Brendel, K., Gross, P.H., Pamukcu, R. and Burt, R.W. Do NSAIDS exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J. Cell. Biochem. 22: 18-23, 1995.
289. Thompson, H.J., Briggs, S., Paranka, N.S., Piazza, G.A., Brendel, K., Gross, P.H., Sped, G.J., Pamukcu, R. and Ahnen, D.J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl. Cancer Inst. 87: 1259-1260, 1995.
290. Ahnen, D., Hixson, L., Alberts, D., Brendel, K., Gross, P., Paranka, N., Burt, R. and Pamukeu, R. Sulindac, and its sulfone metabolite (FGN-1), both inhibit rat colon carcinogenesis but neither inhibit colonic proliferation. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 631, abstract no. 3763, 1994.
291. Piazza, G.A., Rahm, A.L.K., Krutzsch, M., Sperl, G., Paranka, N.S., Gross, P.H., Brendel, K., Burt, R.W., Alberts, D.S., Pamukeu, R. and Ahnen, D.J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55: 3110-3116, 1995.
292. IARC Working Group Tea. IARC Monogr. 51: 207-271, 1991.
293. Multiple authors. Abstracts of papers presented at the First International Symposium on the Physiological and Pharmacological Effects of Camellia sinensis (tea). Prev. Med. 21: 331-333, 1992.
294. Yang, C.S. and Wang, Z.-Y. Tea and cancer. J. Natl. Cancer Inst. 85: 1038-1049, 1993.
295. Zatonski, W.A., La Vecchia, C., Przewozniak, K., Maisonneuve, P., Lowenfels, A.B. and Boyle, P. Risk factors for gallbladder cancer A polish case-control study. Int. J. Cancer 51: 707-711, 1992.
296. Stocks, P. Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee. Br. J. Cancer 24: 215-225, 1970.
297. Zheng, W., Doyle, T.J., Hong, C.P., Kushi, L.H., Sellers, T.A. and Folsom, A.R. Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36: 278, abstract no. 1654, 1995.
298. Zatonski, W.A., Boyle, P., Przewozniak K., Maisonneuve, P., Drosik, K. and Walker, A.M. Cigarette smoking, alcohol, tea and coffee consumption and pancreas cancer risk: A case-control study from Opole, Poland. Int. J. Cancer 53: 601-607, 1993.
299. Yamane, T., Hagiwara, N., Tateishi, M., Akachi, S., Kim, M., Okuzumi, J., Kitao, Y., Inagake, M., Kuwata, K. and Takahashi, T. Inhibition of azoxymethane-induced colon carcinogenesis in rat by green tea polyphenol fraction. Jpn. J. Cancer Res. 82: 1336-1339, 1991.
300. Yin, P.-Z., Zhao, J.-Y., Cheng, S.-J., Kara, Y., Zhu, Q.- F. and Liu, Z.-G. Experimental studies of the inhibitory effects of green tea catechin on mice large intestinal cancers induced by 1,2-dimethylhydrazine. Cancer Lett. 79: 33-38, 1994.
301. Fujita, Y., Yamane, T., Tanaka, M., Kuwata, K., Okuzumi, J., Takahashi, T., Fujiki, H. and Okuda, T. Inhibitory effect of (-)-epigallocatechin gallate on carcinogenesis with N-ethyl-N'-nitro-N-nitrosoguanidine in mouse duodenum. Jpn. J. Cancer Res. 80: 503-505, 1989.
302. Fujiki, H., Yoshizawa, S., Horiuchi, T., Suganuma, M., Yatsunami, J., Nishiwaki, S., Okabe, S., Nishiwaki-Matsushima, R., Okuda, T. and Sugimura, T. Anticarcinogenic effects of (-)-epigallocatechin gallate. Prev. Med. 21: 503-509, 1992.
303. Xu, Y. and Han, C. The effect of Chinese tea on the occurrence of esophageal tumors induced by N-nitrosomethylbenzylamine formed in vivo. Biomed. Environ. Sci. 3: 406-412, 1990.
304. Chen, J. The effects of Chinese tea on the occurrence of esophageal tumors induced by N-nitrasomethylbenzylamine in rats. Prev. Med. 21: 385-391, 1992.
305. Wang, Z.Y., Agarwal, W. R., Khan, W.A. and Mukhtar, H. Protection against benzo[a]pyrene- and N-nitrosodiethylamine-induced lung and fbrestomach tumorigenesis in A/J mice by water extracts of green tea and licorice. Carcinogenesis 13: 1491-1494, 1992.
306. Katiyar, S.K., Agarwal, R., Zaim, M.T. and Mukhtar, H. Protection against N-nitrosodiethylamine and benzo [a]pyrene-induced forestomach and lung tumorigenesis in A/J mice by green tea. Carcinogenesis 14: 849-855, 1993.
307. Wang, Z.Y., Hong, J.-Y., Huang, M.-T., Reuhl, K.R., Conney, A.H. and Yang, C.S. Inhibition of N-nitrosodiethylamine- and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mice by green tea and black tea. Cancer Res. 52: 1943-1947, 1992.
308. Yang, C.S., Wang, Z.-Y. and Hong, J.-Y. Inhibition of tumorigenesis by chemicals from garlic and tea. Adv. Exp. Med. Biol. 354: 113-122, 1994.
309. Conney, A.H., Wang, Z.-Y., Huang, M.-T., Ho, C.-T. and Yang, C.S. Inhibitory effect of green tea on tumorigenesis by chemicals and ultraviolet light. Prev. Med. 21: 361-369, 1992.
310. Yuan, L. Comparative study on the inhibitory effect of green tea, coffee and levamisole on the hepatocarcinogenic action of diethylnitrosamine. Chung Hua Chung Liu Tsa Chih 13: 193-195, 1991.
311. Katiyar, S.K., Agarwal, R. and Mukhtar, H. Protective effects of green tea polyphenols administered by oral intubation against chemical carcinogen-induced forestomach and pulmonary neoplasia in A/J mice. Cancer Lett. 73: 167-172, 1993.
312. Katiyar, S.K., Agarwal, R. and Mukhtar, H. Protection against diethylnitrosamine (DEN)- and benzo(a)pyrene-(BP) induced forestomach and pulmonary neoplasia in A/J mice by limited oral intubation of green tea polyphenols. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 626, abstract no. 3731, 1994.
313. Wang, Z.Y., Hong, J.-Y., Shi, S.T., Lee, M.J. Sun, Y., Conney, A.H. and Yang, C.S. Inhibitory effects of diallyl sulfone (DASO2) and green tea on lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A/J mice. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 625, abstract no. 3728, 1994.
314. Tao, S., Wang, Z.-Y., Smith, T.J., Hong, J.-Y., Chen, W.-F., Ho, C.-T. and Yang, C.S. Effects of green tea and black tea on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation, DNA methylation, and lung tumorigenesis in A/J mice. Cancer Res. 54: 4641-4647, 1994.
315. Xu, Y., Ho, C.-T., Amin, S.G., Han, C. and Chung, F.-L. Inhibition, of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res. 52: 3875-3879, 1992.
316. Chung, F.L., Morse, M.A., Eklind, K.I., Xu, Y., Rylander, R. and Krinsky, N. Inhibition of the tobacco-specific nitrosamine-induced lung tumorigenesis by compounds derived from cruciferous vegetables and green tea. Ann. N.Y. Acad. Sci. 686: 186-202, 1993.
317. Hirose, M., Hoshiya, T., Akagi, K., Futakuchi, M. and Ito, N. Inhibition of mammary gland carcinogenesis by green tea calechins and other naturally occurring antioxidants in female Sprague-Dawley rats pretreated with 7,12-dimethyl-benz[a]anthracene. Cancer Lett. 83: 149-156, 1994.
318. Hirose, M., Akagi, K., Hasegawa, R., Yaono, M., Satoh, T., Kara, Y., Wakabayashi, K. and Ito, N. Chemoprevention of 2-amino-1-niethyl-6-phenylimidazo[4,5-b]-pyridine (PhIP)-induced mammary gland carcinogenesis by antioxidants in F344 female rats. Carcinogenesis 16: 217-221, 1995.
319. Mukhtar, H., Katiyar, S.K. and Agarwal, R. Cancer chemoprevention by green tea components. Adv. Exp. Med. Biol. 354: 123-134, 1994.
320. Mukhtar, H., Wang, Z.Y., Katiyar, S.K. and Agarwal, R. Tea components: Antimutagenic and anticarcinogenic effects. Prev. Med. 21: 351-360, 1992.
321. Han, J. Highlights of the cancer chemoprevention studies in China. Prev. Med. 22: 712-722, 1993.
322. Fujiki, H., Suganuma, M., Komori, A., Yatsunami, J., Okabe, S., Ohta, T. and Sueoka, E. A new tumor promotion pathway and its inhibitors. Cancer Detect. Prev. 18: 1-7, 1994.
323. Bayerdorffer, E., Mannes, G.A., Richter, W.O., Ochsenkuhn, T., Wiebecke, B., Kopeke, W. and Paumgartner, G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 104: 145-151, 1993.
324. Guldutuna, S., Zimmer, G., Imhof, M., Bhatti, S., You, T. and Leuschner, U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 104: 1736-1744, 1993.
325. Kurtz, W.J.O., Guldutuna, S. and Leuschner, U. Differing effect of chenodeoxycholic acid and ursodeoxycholic acid on bile acids in rat colonic wall and contents. Tokai J. Exp. Clin. Med. 13: 91-97, 1988.
326. Earnest, D.L., Holubec, H., Wali, R.K., Jolley, C.S., Bissonette, M., Bhattacharyya, A.K., Roy, H., Khare, S. and Brasitus, T.A. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 54: 5071-5074, 1994.
327. Duffy, M.A. (ed.) Physicians' Desk Reference. Montvale: Medical Economics Data, 1995, pp. 2452-2453.
328. Garland, C.F. and Garland, F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int. J. Epidemiol. 9: 227-231, 1980.
329. Garland, F.C., Garland, C.F., Gorham, E.D. and Young, J.F. Geographic variation in breast cancer mortality in the United States. Prev. Med. 19: 614-622, 1990.
330. Gorham, E.D., Garland, F.C. and Garland, C.F. Sun light and breast cancer incidence in the USSR. Int. J. Epidemiol. 19: 820-824, 1990.
331. Bostick, R.M., Potter, J.D., Sellers, T.A., McKenzie, D.R., Kushi, L.H. and Folsom, A.R. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am. J. Epidemiol. 137: 1302-1317, 1993.
332. Manchette, C.L. and Schwartz, G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861-2869, 1992.
333. Emerson, J.C. and Weiss, N.S. Colorectal cancer and solar radiation. Cancer Causes Control 3: 95-99, 1992.
334. Garland, C., Barrett-Connor, E., Rossof, A.H., Shekelle, R.B., Criqui, M.H. and Paul, O. Dietary vitamin D and calcium and risk of colorectal cancer: A 19-year prospective study in men. Lancet 1: 307-309, 1985.
335. Garland, C.F., Garland, F.C., Shaw, E.K., Comstock, G.W., Helsing, K.J. and Gorham, E.D. Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 2: 1176-1178, 1989.
336. Garland, C.F., Garland, F.C. and Gorham, E.D. Can colon cancer incidence and death rates be reduced with calcium and vitamin ?D. Am. J. Clin. Nutr. 54: 193S-201S, 1991.
337. Corder, E.H., Guess, H.A., Hulka, B.S., Friedman, G.D., Sadler, M., Vollmer, R.T., Lobaugh, B., Drezner, M.K., Vogelman, J.H. and Orentreich, N. Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. 2: 467-472, 1993.
338. Garland, C.F., Garland, F.C and Gorham, E.D. Colon cancer parallels rickets. In: Lipkin, M., Newmark, H.L. and Kelloff, G. (eds.) Calcium, Vitamin D, and Prevention of Colon Cancer. Boca Raton: CRC Press, 1991, pp. 81-109.
339. Olsen, S.J. and Love, R.R. A new direction in preventive oncology: Chemoprevention. Semin. Oncol. Nurs. 2: 211-221, 1986.
340. Vogel, V.G. and McPherson, R.S. Dietary epidemiology of colon cancer. Hematol. Oncol. Clin. North Am. 3: 35-63, 1989.
341. Okamura, W.H., Palenzuela, J.A., Plumet, J. and Midland, M.M. Vitamin D: Structure-function analyses and the design of analogs. J. Cell. Biochem. 49: 10-18, 1992.
342. Pols, H.A.P., Birkenhager, J.C. and van Leeuwen, J.P.T.M. Vitamin D analogues: From molecule to clinical application. Clin. Endocrinol. 40: 285-291, 1994.
343. Correia, M.A. and Castagnoli, N., Jr. Drug biotransformation. In: Katzung, B.G. (ed.) Basic and Clinical Pharmacology. 4th ed., Norwalk, CT: Appleton and Lange, 1989, pp. 41-50.
344. DeLuca, H.F. Current views of the functions and molecular mechanism of action of vitamin D. Proc. Natl. Acad. Sci. USA 34: 619-620, 1993.
345. Skowronski, R.J., Peehl, D.M. and Feldman, D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960, 1993.
346. 3 and its analogs on human colon adenocarcinoma cells (CaCo-2): Influence of extracellular calcium. Biochem. Biophys. Res. Commun. 179: 57-62, 1991.
347. Colston, K.W., Chander, S.K., Mackay, A.G. and Coombes, R.C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol. 44: 693-702, 1992.
348. 3: Differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res. 50: 6857-6864, 1990.
349. Studzinski, G.P., McLane, J.A. and Uskokovic, M.R. Signaling pathways for vitamin D-induced differentiation: Implications for therapy of proliferative and neoplastic diseases. Crit. Rev. Eukaryot. Gene Expr. 3: 279-312, 1993.
350. Reitsma, P.H., Rothberg, P.G., Astrin, S.M., Trial, J., BarShavit, Z., Hall, A., Teitelbaum, S.L. and Kahn, A.J. Regulation of wyc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 306: 492-494, 1983.
351. Koizumi, T., Nakao, Y., Kawanishi, M., Maeda, S., Sugiyama, T. and Fujita, T. Suppression of c-myc mRNA expression by steroid hormones in HTLV-1-infected T-cell line, KH-2. Int. J. Cancer 44: 701-706, 1989.
352. 3, precedes down regulation of the c-myc gene. J. Cell. Physiol. 128: 171-179, 1986.
353. Karmali, R., Hewison, M., Rayment, N., Farrow, SM., Brennan, A., Katz, D.R. and O'Riordan, J.L.H. 1,25(OH)2D3 regulates c-myc mRNA levels in tonsillar T-lymphocytes. Immunology 74: 589-593, 1991.
354. 3 (VitD) inhibit colonic ornithine decarboxylase (ODC) activity induced by bile acids. FASEB J. 3: A469, abstract no. 1411, 1989.
355. Wiseman, H. Vitamin D is a membrane antioxidant Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. FEBS Lett. 326: 285-288, 1993.
356. Colston, K.W., Berger, U. and Coombes, R.C. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1: 188-191, 1989.
357. DeLuca, H.F. New concepts of vitamin D functions. Ann. N.Y. Acad. Sci. 669: 59-69, 1992.
358. 3. Proc. Natl. Acad. Sci. USA 78: 4990-4994, 1981.
359. Cross, H.S., Pavelka, M., Slavik, J. and Peterlik, M. Growth control of human colon cancer by vitamin D and calcium in vitro. J. Natl. Cancer Inst. 84: 1355- 1357, 1992.
360. 3 increases epidermal growth factor receptors and transforming growth factor β-like activity in a bone-derived cell line. J. Biol. Chem. 262: 13424-13428, 1987.
361. Letterio, J.J., Anzano, M.A., Roberts, A.B. and Sporn, M.B. Novel vitamin D analog enhances differentiating effects of transforming growth factor β-1 (TGF-B) in myeloid leukemic cell lines. Proc. Annu. Meet. Am. Assoc. Cancer Res. 34: 46, abstract no. 274, 1993.
362. 3: Towards an endocrine therapy of brain tumors? J. Neurosci. Res. 37: 271-277, 1994.
363. Reichel, H., Koeffler, H.P. and Norman, A.W. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320: 980-991, 1989.
364. 3 or its derivatives. J. Biol. Chem. 269: 2971-2981, 1994.
365. Munker, R., Norman, A. and Koeffler, H.P. Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. J. Clin. Invest. 78: 424-430, 1986.
366. Kolla, S.S., Moore, D.C. and Studzinski, G.P. Vitamin D analogs inhibit erythroid differentiation and induce monocytic differentiation of leukemic cells with the same relative potency. Proc. Soc. Exp. Biol. Med. 197: 214-217, 1991.
367. 3. Cancer Res. 52: 515-520, 1992.
368. 3. In: Huberman, E. and Barr, S.H. (eds.) Carcinogenesis - A Comprehensive Survey}. New York: Raven Press, 1985, pp. 275-286.
369. 3 and three analogs in colon carcinoma cell lines. Proc. Annu. Meet. Am. Assoc. Cancer Res. 34: 244, abstract no. 1453, 1993.
370. 3 on proliferation and differentiation of Caco-2 cells. Endocrinology 134: 1710-1717, 1994.
371. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 78: 75-82, 1991.
372. 3. Carcinogenesis 9: 187-190, 1988.
373. 3 in chemically induced rat colon carcinogenesis. Carcinogenesis 13: 2293-2298, 1992.
374. 3. Cancer Res. 45: 5426-5430, 1985.
375. 3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem. Biophys. Res. Commun. 116: 605-611, 1983.
376. Anzano, M.A., Smith, J.M., Uskokovic, M.R., Peer, C.W., Mullen, L.T., Letterio, J.J., Welsh, M.C., Shrader, M.W., Logsdon, D.L., Driver, C.L., Brown, C.C., Roberts, A.B. and Sporn, M.B. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. 54: 1653-1656, 1994.
377. Anzano, M., Smith, J., Peer, C., Welsh, M., Brown, C. and Sporn, M. Vitamin D analog synergizes with tamoxifen in prevention of mammary carcinogenesis. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35: 623, abstract no. 3713, 1994.
378. 3 and analogs. J. Cell. Biochem. 20: 268-281, 1994.
379. Garland, M., Stampfer, M.J., Willett, W.C. and Hunter, D.J. The epidemiology of selenium and human cancer. In: Frei, B. (ed.) Natural Antioxidants in Human Health and Disease. San Diego: Academic Press, 1994, pp. 263-286.
380. Salonen, J.T., Salonen, R., Lappetelainen, R., Maenpaa, P.H., Alfthan, G. and Puska, P. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: Matched case-control analysis of prospective data. Br. Med. J. 290: 417-420, 1985.
381. Kok, F.J., deBruijn, A.M., Hofman, A., Vermeeren, R. and Valkenburg, H.A. Is serum selenium a risk factor for cancer in men only? Am. J. Epidemiol. 125: 12-16, 1987.
382. Clark, L.C., Cantor, K.P. and Allaway, W.H. Selenium in forage crops and cancer mortality in U.S. counties. Arch. Environ. Health 46: 37-42, 1991.
383. Clark, L.C., Hixson, L.J., Combs, G.F., Jr., Reid, M.E., Turnbull, B.W. and Sampliner, R.E. Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol. Biomarkers Prev. 2: 41-46, 1993.
384. Schrauzer, G.N., White, D.A. and Schneider, C.J. Cancer mortality correlation studies - III: Statistical associations with dietary selenium intakes. Bioinorg. Chem. 7: 23-34, 1977.
385. Criqui, M.H., Bangdiwala, S., Goodman, D.S., Blaner, W.S., Morris, S., Kritchevsky, S., Lippel, K., Mebane, I. and Tyroler, H.A. Selenium, retinol, retinol-binding protein, and uric acid associations with cancer mortality in a population-based prospective case-control study. Ann. Epidemiol. 1: 385-393, 1991.
386. Willett, W.C., Morris, J.S., Pressell, S., Taylor, J.O., Polk, B.F., Stampfer, M.J., Rosner, B., Schneider, K. and Hames, C.G. Prediagnostic serum selenium and risk of cancer. Lancet 2: 130-134, 1983.
387. Whanger, P.D. Selenium in the treatment of heavy metal poisoning and chemical carcinogenesis. J. Trace Elem. Electrolytes Health Dis. 6: 209-221, 1992.
388. Vernie, L.N. Selenium in carcinogenesis. Biochim. Bio phys. Acta 738: 203-217, 1984.
389. Combs, G.F., Jr. and Combs, S.B. The nutritional biochemistry of selenium. Annu. Rev. Nutr. 4: 257-280, 1984.
390. Ip, C., Hayes, C., Budnick, R.M. and Ganther, H.E. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res. 51: 595-600, 1991.
391. El-Bayourny, K., Chae, Y.-H., Upadhyaya, P., Meschter, C., Cohen, L.A. and Reddy, B.S. Inhibition of 7,12-dimethyl-benz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound, 1,4-phenylenebis- (methylene)selenocyanate. Cancer Res. 52: 2402-2407, 1992.
392. Ip, C., El-Bayoumy, K., Upadhyaya, P., Ganther, H., Vadhanavikit, S. and Thompson, H. Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. Carcinogenesis 15: 187-192, 1994.
393. Reddy, B.S., Rivenson, A., Kulkarni, N., Upadhyaya, P. and El-Bayoumy, K. Chemoprevention of colon carcinogenesis by the synthetic organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Res. 52: 5635-5640, 1992.
394. El-Bayoumy, K., Upadhyaya, P., Desai, D.H., Amin, S. and Hecht, S.S. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenicity in mouse lung by the synthetic organoselenium compound, 1,4-phenylene-bis(methylene)selenocyanate. Carcinogenesis 14: 1111-1113, 1993.
395. El-Bayoumy, K., Rivenson, A., Upadhyaya, P., Sohn, O.S., Fiala, E.S., Kulkarni, N. and Reddy, B.S. Chemopreventive efficacy of dietary 1,4-phenylenebis(methylene)selenocyanats (XSC) on azoxymethane-induced colon carcinogenesis in rats. Proc. Annu. Meet. Am. Assoc. Cancer Res. 33: 160, abstract no. 961, 1992.
396. Prokopczyk, B., Upadhyaya, P., Amin, S., Desai, D., Hoffmann, D. and El-Bayoumy, K. The effects of selenium compounds on DNA adduct formation in rats and mice after treatment with 4-(methylrdtrosamino)-1-(3-pyridyl)-1-butanone (NNK). Proc. Annu. Meet. Am. Assoc. Cancer Res. 36:593, abstract no. 3532, 1995.
397. Sohn, O.S., Fiala, E.S., Surace, A., Chae, Y.-H., Upadhyaya, P. and El-Bayoumy, K. Effects of organoselenium chemopreventive agents on xenobiotic metabolizing enzymes. Proc. Annu. Meet. Am. Assoc. Cancer Res. 34: 125, abstract no. 743, 1993.
398. Thompson, H.J., Wilson, A., Lu, J., Singh, M., Jiang, C., Upadhyaya, P., El-Bayoumy, K. and Ip, C. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 15: 183-186, 1994.
399. Tillotson, J.K., Upadhyaya, P. and Ronai, Z. Inhibition of thymidine kinase in cultured mammary tumor cells by the chemopreventive organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate. Carcinogenesis 15: 607-610, 1994.
400. Kohrle, J. Thyroid hormone deiodination in target tissues - A regulatory role for the trace element selenium? Exp. Clin. Endocrinol. 102: 63-89, 1994.
401. Lubet, R.A., Steele, V.E., Casebolt, T.L., Eto, I., Kelloff, G.J. and Grubbs, C.J. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 15: 2775-2780, 1994.
402. Troll, W. and Kennedy, A.R. Workshop report from the Division of Cancer Etiology, National Cancer Institute, National Institutes of Health. Protease inhibitors as cancer chemopreventive agents. Cancer Res. 49: 499-502, 1989.
403. Kennedy, A.R. and Manzone, H. Effects of protease inhibitors on levels of proteorytic activity in normal and premalignant cells and tissues. J. Cell. Biochem. 22: 188-194, 1995.
404. Nishino, H. Cancer chemoprevention by natural carotenoids and their related compounds. J. Cell. Biochem. 22: 231-235, 1995.
405. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Group The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330: 1029-1035, 1994.
406. Ip, C. Interaction of vitamin C and selenium supple mentation in the modification of mammary carcinogenesis in rats. J. Natl. Cancer Inst. 77: 299-234, 1986.
407. Ip, C. and White, G. Mammary cancer chemoprevention by inorganic and organic selenium: Single agent treatment or in combination with vitamin E and their effects on in vitro immune functions. Carcinogenesis 8: 1763-1766, 1987.
408. Cukierski, M.J., Willhite, C.C., Lasley, B.L., Hendrie, T.A., Book, S.A., Cox, D.N. and Hendrickx, A.G. 30-Day oral toxicity study of L-selenomethionine in female long-tailed macaques (Macaca fascicularis). Fundam. Appl. Toxicol. 13: 26-39, 1989.
409. Ip, C. and Lisk, D.J. Characterization of tissue selenium profiles and anticarcinogenic responses in rats fed natural sources of selenium-rich products. Carcinogenesis 15: 573-576, 1994.
410. Thompson, H.J., Meeker, L.D. and Kokoska, S. Effect of an inorganic and organic form of dietary selenium on the promotional stage of mammary carcinogenesis in the rat. Cancer Res. 44: 2803-2806, 1984.
411. Kelloff, G.J., Fay, J.R., Steele, V.E., Lubet, R.A., Boone, C.W., Crowell, J.A. and Sigman, C.C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prev. 5: 657-666, 1996.
412. Kohl, N.E., Conner, M.W., Gibbs, J.B., Graham, S.L., Hartman, G.D. and Oliff, A. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J. Cell. Biochem. 22: 145-150, 1995.
413. Kohl, N.B., Omer, C.A., Conner, M.W., Anthony, N.J., Davide, J.P., DeSolms, S.J., Giuliani, E.A., Gomez, R.P., Graham, S.L., Hamilton, K., Handt, L.K., Hartman, G.D., Koblan, K.S., Krai, A.M., Miller, P.J., Mosser, S.D., O'Neill, T.J. et al. Inhibition of farnesyl transferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1: 792-797, 1995.